Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7226975 | 0.89 | ACACB (0.39) | HRH3ACACBLRRK2 | |
| SCHEMBL4725119 | 0.89 | ACACB (0.39) | HRH3ACACBLRRK2 | |
| SCHEMBL333383 | 0.85 | HRH1 (0.43) | HRH1HRH3PARP10 | |
| SCHEMBL6531748 | 0.81 | PARP10 (0.35) | HRH3ACACBAPPPARP10 | |
| SCHEMBL231982 | 0.81 | PARP10 (0.48) | HRH1HRH3ACACBPARP10 | |
| SCHEMBL21281 | 0.81 | PARP10 (0.44) | HRH1HRH3PARP10 | |
| SCHEMBL6531997 | 0.80 | ACACB (0.38) | HRH3ACACBLRRK2 | |
| SCHEMBL676960 | 0.79 | PARP10 (0.43) | HRH1HRH3PARP10 | |
| SCHEMBL2924302 | 0.79 | PARP10 (0.43) | HRH1HRH3PARP10 | |
| SCHEMBL22392 | 0.79 | PARP10 (0.43) | HRH1HRH3PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-25 | — | — | US | claimed |
| EP-3294705-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | The Wistar Institute Of Anatomy And Biology (US) | 2018-03-21 | — | — | EP | claimed |
| WO-2017180571-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | claimed |
| WO-2016183534-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2016-11-17 | — | — | WO | claimed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | claimed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | claimed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | claimed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| EP-1753735-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | Transtech Pharma, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | claimed |
| WO-2005103022-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | TRANSTECH PHARMA, INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3068758-B1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3294705-B1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-04-20 | — | — | US | disclosed |
| CN-1630835-A | Acid-decomposable resin composition containing ketone-aldehyde copolymer | NIPPON SODA CO (JP) | 2005-06-22 | — | — | CN | disclosed |
| CN-1592738-A | Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition | WAKO PURE CHEM IND LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| WO-2004096213-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | SYK 1632/4885KAT2B 1038/4885BAZ2B 1034/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | SYK 1457/4885KAT2B 1842/4885BAZ2B 998/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | SYK 3510/4885KAT2B 1799/4885BAZ2B 729/4885 |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | SYK 1632/4885KAT2B 1038/4885BAZ2B 1034/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | SYK 2433/4885KAT2B 343/4885BAZ2B 1288/4885 |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | SYK 3188/4885KAT2B 1693/4885BAZ2B 4292/4885 |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | SYK 1632/4885KAT2B 1038/4885BAZ2B 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.